logo-loader
viewOpen Orphan PLC

Open Orphan catching global attention with 'stunning' FLU-v results & world-first coronavirus study

Open Orphan PLC's (LON:ORPH) Cathal Friel and its subsidiary hVIVO's chief scientist Dr Andrew Catchpole sat down with Proactive London's Andrew Scott.

This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they're jointly developing have been published in a peer-reviewed journal.

The data from the FLU-v 003 phase IIb study of the FLU-v vaccine appeared in the Annals of Internal Medicine periodical.

Also this week hVIVO began developing the world’s first human coronavirus challenge study.

hVIVO owns Europe's only quarantine clinic with an onsite virology lab where the challenge model will be developed and used.

Quick facts: Open Orphan PLC

Price: 15.8 GBX

AIM:ORPH
Market: AIM
Market Cap: £93.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan's Cathal Friel on its £12mln raise to accelerate coronavirus...

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing they've raised approximately £12mln to ramp up its coronavirus (COVID-19) antiviral testing. Friel says the fundraise has brought many new leading blue-chip institutional shareholders to their...

1 week, 3 days ago

2 min read